Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.58 |
| ▸ | CA1 | P00915 | 7/20 | 0.58 |
| ▸ | CA9 | Q16790 | 7/20 | 0.58 |
| ▸ | CA12 | O43570 | 3/20 | 0.58 |
| ▸ | CA7 | P43166 | 3/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | MET | P08581 | 7/20 | 0.53 |
| ▸ | ATR | Q13535 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2343456 | 1.00 | CA2 (0.58) | CA2CA1CA9CA12CA7 | |
| SCHEMBL12392721 | 0.88 | HRH3 (0.60) | HRH3MET | |
| SCHEMBL12392956 | 0.88 | HRH3 (0.60) | HRH3MET | |
| SCHEMBL2346243 | 0.87 | HRH3 (0.59) | HRH3METATR | |
| SCHEMBL2346240 | 0.87 | HRH3 (0.59) | HRH3METATR | |
| SCHEMBL2348211 | 0.85 | HRH3 (0.62) | HRH3METATR | |
| SCHEMBL2348209 | 0.85 | HRH3 (0.62) | HRH3METATR | |
| SCHEMBL3377244 | 0.85 | HRH3 (0.55) | HRH3MET | |
| SCHEMBL2348768 | 0.85 | HRH3 (0.57) | HRH3MET | |
| SCHEMBL2349781 | 0.85 | HRH3 (0.57) | HRH3METATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-02-25 | — | — | US | disclosed |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-02-25 | — | — | US | disclosed |
| EP-1735278-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7632857-B2 | (3-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone; treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632857-B2 | (3-Fluoro-4'-methanesulfonyl-biphenyl-4-yl)-[2-(S)-(2-(R)-methyl-pyrrolidin-1-ylmethyl)-pyrrolidin-1-yl]-methanone; treatment of obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | CA2 1259/4885CA1 859/4885CA9 2005/4885 |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | CA2 1259/4885CA1 859/4885CA9 2005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.